Acute Pancreatitis in Japan

Ikeda, Mio; Hamada, Shin; Kikuta, Kazuhiro; Takikawa, Tetsuya; Yoshida, Naoki; Matsumoto, Ryotaro; Tanaka, Yu; Kataoka, Fumiya; Sasaki, Akira; Tarasawa, Kunio; Fujimori, Kenji; Fushimi, Kiyohide; Masamune, Atsushi

doi:10.1097/mpa.0000000000002009

Cited by 4 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7,8] Current guidelines recommend LC within 2-4 weeks post-MABP discharge to prevent recurrent biliary events that could lead to readmission, increased morbidity, and additional costs. [9][10][11][12][13][14][15] Nevertheless, many institutions tend to postpone LC for 6-12 weeks, awaiting normalization of laboratory values and relief of abdominal pain due to concerns about complications associated with early surgical intervention. [16] Previous studies have endorsed early LC (ELC) as an effective treatment for MABP patients, leading to reduced recurrent biliary events, postoperative complications, readmission, and length of stay.…”

Section: Introductionmentioning

confidence: 99%

Early versus Delayed Laparoscopic Cholecystectomy for Mild Acute Biliary Pancreatitis: A Systematic Review and Meta-Analysis

Zhou,

Zhang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Laparoscopic cholecystectomy (LC) is widely accepted as the definitive therapeutic approach for MABP, primarily aiming to reduce recurrent biliary complications. However, the optimal timing of LC remains a matter of debate. The aim of this study was to evaluate the efficacy and safety of early laparoscopic cholecystectomy (ELC) versus delayed laparoscopic cholecystectomy (DLC) in patients with mild acute biliary pancreatitis (MABP). Methods The PubMed, Embase, Scopus, and CENTRAL databases were systematically searched for randomized clinical trials (RCTs) comparing ELC with DLC in patients with MABP from inception to August 1, 2023. The primary outcome was recurrent biliary events. Secondary outcomes included postoperative complications, readmissions, and length of stay (LOS). The pooled risk ratio (RR) or standardized mean difference (SMD) of data was calculated using the random-effects model. Results Fifteen RCTs with 1616 patients enrolled between 2010 and 2022 were included. High-certainty evidence from nine RCTs demonstrated a significantly lower risk of recurrent biliary events in patients who underwent ELC during the waiting time compared to DLC (RR=0.128[0.063, 0.262], P<0.001). For secondary outcomes, ELC in patients with MABP was associated with a significantly lower readmission rate (RR=0.382[0.182, 0.801], P=0.011) and shorter LOS (SMD=-2.026[-2.854, -1.198], P<0.001) than DLC. Subgroup analysis indicated that patients with ELC had a significantly lower rate of postoperative complications in accordance with the Atlanta criteria, MABP, and >4 weeks subgroup. Conclusions ELC emerges as a generally safe and effective strategy in reducing recurrent biliary events, postoperative complications, readmission, and length of stay for patients with MABP.

show abstract

Section: Introductionmentioning

confidence: 99%

Early versus Delayed Laparoscopic Cholecystectomy for Mild Acute Biliary Pancreatitis: A Systematic Review and Meta-Analysis

Zhou,

Zhang,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Severity of acute pancreatitis in patients with inflammatory bowel disease in the era of biologics: A propensity‐score‐matched analysis using a nationwide database in Japan

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and Aim Acute pancreatitis (AP) is a rare extraintestinal manifestation of inflammatory bowel disease (IBD). Several studies from Western countries have reported that the severity of AP in patients with IBD is similar to that in the general population; however, its severity in patients from Eastern countries in the era of biologics remains unclear. This study aimed to investigate the severity of AP in patients with IBD and the effect of biologics on the severity of AP using a nationwide database. Methods We divided 1138 eligible AP admissions from the Diagnosis Procedure Combination database system into IBD and non‐IBD groups after propensity score matching, and compared the severity of AP. We divided the IBD group into ulcerative colitis (UC) and Crohn's disease (CD) subgroups and compared each with the non‐IBD group. Logistic regression analysis was conducted to identify the clinical factors affecting acute pancreatitis. Results IBD and UC groups had lower rate of severe AP compared to the non‐IBD group (13.7% vs 28.3%, P < 0.0001 and 11.0% vs 28.3%, P < 0.0001, respectively). There were no differences in the rates of severe AP between the CD and non‐IBD groups. Multivariate analysis showed that biologics did not affect the severity of AP. Conclusion The severity of AP in patients with IBD may be lower than that in the general population; biologics for IBD may not worsen its severity. Further prospective studies are required to clarify the severity of AP in patients with IBD.

show abstract

Trends and clinical characteristics of pediatric acute pancreatitis patients in Japan: A comparison with adult cases based on a national administrative inpatient database

Ikeda,

Kikuta,

Hamada

et al. 2023

Pancreatology

View full text Add to dashboard Cite

Acute Pancreatitis in Japan

Cited by 4 publications

References 33 publications

Early versus Delayed Laparoscopic Cholecystectomy for Mild Acute Biliary Pancreatitis: A Systematic Review and Meta-Analysis

Early versus Delayed Laparoscopic Cholecystectomy for Mild Acute Biliary Pancreatitis: A Systematic Review and Meta-Analysis

Severity of acute pancreatitis in patients with inflammatory bowel disease in the era of biologics: A propensity‐score‐matched analysis using a nationwide database in Japan

Trends and clinical characteristics of pediatric acute pancreatitis patients in Japan: A comparison with adult cases based on a national administrative inpatient database

Contact Info

Product

Resources

About